Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 5, 2025, 5:35 pm

Quick Insight

Vaishali Pharma Ltd's current market capitalization stands at ₹127 Cr., with a high P/E ratio of 319 indicating overvaluation. The return on equity (ROE) and return on capital employed (ROCE) are notably low at 1.52% and 4.19%, respectively, suggesting inefficiencies in capital utilization. Operating profit margin (OPM) is at 5.77%, reflecting tight profit margins. The company's net profit is at ₹0.82 Cr., with reserves of ₹38.82 Cr. Borrowings are at ₹12.32 Cr., and the company's cash conversion cycle (CCC) is at 77 days, indicating a need for improved working capital management. With a price-to-book value (P/BV) ratio of 2.53x and interest coverage ratio (ICR) of 2.08x, investors should exercise caution due to the high valuation and low profitability metrics present in this analysis.

Competitors of Vaishali Pharma Ltd

All Competitor Stocks of Vaishali Pharma Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:35 am

Below is a detailed analysis of the quarterly data for Vaishali Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 23.75 Cr.. The value appears to be declining and may need further review. It has decreased from 32.25 Cr. (Mar 2025) to 23.75 Cr., marking a decrease of 8.50 Cr..
• For Expenses, as of Jun 2025, the value is 22.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 38.29 Cr. (Mar 2025) to 22.38 Cr., marking a decrease of 15.91 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.37 Cr.. The value appears strong and on an upward trend. It has increased from -6.04 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 7.41 Cr..
• For OPM %, as of Jun 2025, the value is 5.77%. The value appears strong and on an upward trend. It has increased from -18.73% (Mar 2025) to 5.77%, marking an increase of 24.50%.
• For Other Income, as of Jun 2025, the value is 0.84 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.16 Cr..
• For Interest, as of Jun 2025, the value is 0.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.44 Cr. (Mar 2025) to 0.33 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Jun 2025, the value is 0.14 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.74 Cr.. The value appears strong and on an upward trend. It has increased from -5.60 Cr. (Mar 2025) to 1.74 Cr., marking an increase of 7.34 Cr..
• For Tax %, as of Jun 2025, the value is 26.44%. The value appears to be increasing, which may not be favorable. It has increased from -23.39% (Mar 2025) to 26.44%, marking an increase of 49.83%.
• For Net Profit, as of Jun 2025, the value is 1.28 Cr.. The value appears strong and on an upward trend. It has increased from -4.29 Cr. (Mar 2025) to 1.28 Cr., marking an increase of 5.57 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from -0.40 (Mar 2025) to 0.12, marking an increase of 0.52.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:33 pm

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: August 11, 2025, 3:03 pm

Below is a detailed analysis of the balance sheet data for Vaishali Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 26.09 Cr.. The value appears strong and on an upward trend. It has increased from 10.72 Cr. (Mar 2024) to 26.09 Cr., marking an increase of 15.37 Cr..
• For Reserves, as of Mar 2025, the value is 38.82 Cr.. The value appears strong and on an upward trend. It has increased from 32.12 Cr. (Mar 2024) to 38.82 Cr., marking an increase of 6.70 Cr..
• For Borrowings, as of Mar 2025, the value is 12.32 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.49 Cr. (Mar 2024) to 12.32 Cr., marking a decrease of 1.17 Cr..
• For Other Liabilities, as of Mar 2025, the value is 32.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.62 Cr. (Mar 2024) to 32.61 Cr., marking an increase of 8.99 Cr..
• For Total Liabilities, as of Mar 2025, the value is 109.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 79.95 Cr. (Mar 2024) to 109.84 Cr., marking an increase of 29.89 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2.08 Cr.. The value appears strong and on an upward trend. It has increased from 1.52 Cr. (Mar 2024) to 2.08 Cr., marking an increase of 0.56 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.74 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.74 Cr..
• For Investments, as of Mar 2025, the value is 0.43 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.43 Cr..
• For Other Assets, as of Mar 2025, the value is 107.33 Cr.. The value appears strong and on an upward trend. It has increased from 77.26 Cr. (Mar 2024) to 107.33 Cr., marking an increase of 30.07 Cr..
• For Total Assets, as of Mar 2025, the value is 109.84 Cr.. The value appears strong and on an upward trend. It has increased from 79.95 Cr. (Mar 2024) to 109.84 Cr., marking an increase of 29.89 Cr..

Notably, the Reserves (38.82 Cr.) exceed the Borrowings (12.32 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Vaishali Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 5. It has decreased from 0.68 (Mar 24) to 0.31, marking a decrease of 0.37.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 5. It has decreased from 0.64 (Mar 24) to 0.31, marking a decrease of 0.33.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 3. It has decreased from 1.14 (Mar 24) to 0.09, marking a decrease of 1.05.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 4.98. It has decreased from 33.41 (Mar 24) to 4.98, marking a decrease of 28.43.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.59. It has decreased from 80.49 (Mar 24) to 7.59, marking a decrease of 72.90.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 2.96 (Mar 24) to 0.25, marking a decrease of 2.71.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 2.48 (Mar 24) to 0.21, marking a decrease of 2.27.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.09. This value is within the healthy range. It has decreased from 0.86 (Mar 24) to 0.09, marking a decrease of 0.77.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has decreased from 0.67 (Mar 24) to 0.06, marking a decrease of 0.61.
• For PBDIT Margin (%), as of Mar 25, the value is 3.32. This value is below the healthy minimum of 10. It has decreased from 3.67 (Mar 24) to 3.32, marking a decrease of 0.35.
• For PBIT Margin (%), as of Mar 25, the value is 2.83. This value is below the healthy minimum of 10. It has decreased from 3.08 (Mar 24) to 2.83, marking a decrease of 0.25.
• For PBT Margin (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 10. It has increased from 1.07 (Mar 24) to 1.23, marking an increase of 0.16.
• For Net Profit Margin (%), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 5. It has decreased from 0.83 (Mar 24) to 0.82, marking a decrease of 0.01.
• For Return on Networth / Equity (%), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 15. It has decreased from 2.00 (Mar 24) to 1.25, marking a decrease of 0.75.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.02. This value is below the healthy minimum of 10. It has decreased from 5.68 (Mar 24) to 4.02, marking a decrease of 1.66.
• For Return On Assets (%), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 5. It has decreased from 0.89 (Mar 24) to 0.74, marking a decrease of 0.15.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.10 (Mar 24) to 0.06, marking a decrease of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has decreased from 0.35 (Mar 24) to 0.17, marking a decrease of 0.18.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.04. It has decreased from 1.09 (Mar 24) to 1.04, marking a decrease of 0.05.
• For Current Ratio (X), as of Mar 25, the value is 2.61. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 2.61, marking an increase of 0.36.
• For Quick Ratio (X), as of Mar 25, the value is 2.49. This value exceeds the healthy maximum of 2. It has increased from 2.24 (Mar 24) to 2.49, marking an increase of 0.25.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.08. This value is below the healthy minimum of 3. It has increased from 1.83 (Mar 24) to 2.08, marking an increase of 0.25.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.52. This value is below the healthy minimum of 3. It has increased from 1.41 (Mar 24) to 1.52, marking an increase of 0.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 144.66. It has decreased from 161.15 (Mar 24) to 144.66, marking a decrease of 16.49.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 1.87 (Mar 24) to 1.76, marking a decrease of 0.11.
• For EV / EBITDA (X), as of Mar 25, the value is 52.78. This value exceeds the healthy maximum of 15. It has increased from 50.82 (Mar 24) to 52.78, marking an increase of 1.96.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
• For Price / BV (X), as of Mar 25, the value is 2.53. This value is within the healthy range. It has decreased from 4.19 (Mar 24) to 2.53, marking a decrease of 1.66.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.66, marking a decrease of 0.08.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness